CLINICAL PROTOCOL AND DATA MANAGEMENT (CPDM) In order to facilitate and standardize the human subjects research infrastructure at the Laura and Isaac Perlmutter Cancer Center (PCC), a centralized Clinical Protocol and Data Management Core (CPDM) promotes, supports, and monitors all cancer-related human subject research. In the current funding period, we substantially upgraded and expanded the organizational structure at PCC to provide improved integration and coordination of our clinical cancer research. The CPDM at PCC, known internally as the Clinical Trials Office (CTO), provides central management and oversight functions to coordinate, facilitate, and report on cancer clinical trials at PCC. The CTO provides support for the Center?s Disease Management Groups (DMGs), its Protocol Review and Monitoring Committee (PRMC), and the Data and Safety Monitoring Committee (DSMC). Members of CTO subunits (described herein) provide infrastructure support to the PRMC at the pre- and post- activation stages. The CTO also manages the clinical research informatics technology, maintains a central repository for all protocols, regulatory documents, consent forms, and data for individual studies, provides a web-based listing of current clinical studies at PCC, and informs PCC faculty at all locations, including satellites, of open clinical trials. Quality assurance functions of the CTO include education and training, monitoring, auditing, and other compliance measures to ensure patient safety, data timeliness and accuracy. The CTO also ensures adherence to local and Federal regulations and NYU Langone Health clinical research policies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-40
Application #
10124336
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-12-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
40
Fiscal Year
2021
Total Cost
Indirect Cost
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Litwinoff, Evelyn M S; Gold, Merav Y; Singh, Karan et al. (2018) Myeloid ATG16L1 does not affect adipose tissue inflammation or body mass in mice fed high fat diet. Obes Res Clin Pract 12:174-186
Snetkova, Valentina; Skok, Jane A (2018) Enhancer talk. Epigenomics 10:483-498
Fan, Xiaozhou; Alekseyenko, Alexander V; Wu, Jing et al. (2018) Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut 67:120-127
Gregory, Ann C; Sullivan, Matthew B; Segal, Leopoldo N et al. (2018) Smoking is associated with quantifiable differences in the human lung DNA virome and metabolome. Respir Res 19:174
Lee, Chul-Hwan; Holder, Marlene; Grau, Daniel et al. (2018) Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2. Mol Cell 70:435-448.e5
Bertrand, Anne; Baron, Maria; Hoang, Dung M et al. (2018) In Vivo Evaluation of Neuronal Transport in Murine Models of Neurodegeneration Using Manganese-Enhanced MRI. Methods Mol Biol 1779:527-541
Taylor, Martin S; Altukhov, Ilya; Molloy, Kelly R et al. (2018) Dissection of affinity captured LINE-1 macromolecular complexes. Elife 7:
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Jung, Seungyoun; Allen, Naomi; Arslan, Alan A et al. (2018) Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts. Int J Cancer 142:262-270
Gong, Yixiao; Lazaris, Charalampos; Sakellaropoulos, Theodore et al. (2018) Stratification of TAD boundaries reveals preferential insulation of super-enhancers by strong boundaries. Nat Commun 9:542

Showing the most recent 10 out of 1170 publications